Duke Cancer Institute researchers have identified potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to backfire, driving hyper-progression of melanoma cells instead of unleashing the immune system to fight them.
Catalent to support manufacturing for Galapagos’ GLPG5101
The CAR-T therapy is aimed at treating relapsed/refractory non-Hodgkin lymphoma. Credit: Chinnapong/Shutterstock. Catalent has entered a strategic partnership with Galapagos to facilitate decentralised manufacturing in